Page 14 - RECCMI_05_2021

Gómez-Traveso T, Jaso-Tejera R, González-Torre-González A, Casuso-Sáenz E, Díez-Herrán N.
Angioedema, uso de IECA e infección por SARS-CoV-2

Bibliografía J Allergy Clin Immunol Pract. 2020; 8(7): 2386-2387. doi: 10.1016/j.
jaip.2020.04.061.
1. Galván Casas C, Català A, Carretero Hernández G, Rodríguez-Jiménez P, 5. Grewal E, Sutarjono B, Mohammed I. Angioedema, ACE inhibitor and CO-
Fernández-Nieto D, Rodríguez-Villa Lario A, et al. Classification of the cu- VID-19. BMJ Case Rep. 2020 Sep 9;13(9):e237888. doi: 10.1136/bcr-2020-
taneous manifestations of COVID-19: a rapid prospective nationwide con- 237888.
sensus study in Spain with 375 cases. Br J Dermatol. 2020; 183(1): 71-77. doi: 6. Cohen AJ, DiFrancesco MF, Solomon SD, Vaduganathan M. Angioedema
10.1111/bjd.19163. in COVID-19. Eur Heart J. 2020; 41(34): 3283-3284. doi: 10.1093/eurheartj/
2. Hassan K. Urticaria and angioedema as a prodromal cutaneous manifes- ehaa452.
tation of SARS-CoV-2 (COVID-19) infection. BMJ Case Rep. 2020; 13(7): 7. Xu H, Zhong L, Deng J, Peng J, Dan H, Zeng X, et al. High expression of ACE2
e236981. doi: 10.1136/bcr-2020-236981. receptor of 2019-nCoV on the epithelial cells of oral mucosa. Int J Oral Sci.
3. Abasaeed Elhag SA, Ibrahim H, Abdelhadi S. Angioedema and urticaria in 2020; 12(1): 8. doi: 10.1038/s41368-020-0074-x.
a COVID-19 patient: A case report and review of the literature. JAAD Case 8. Makani H, Messerli FH, Romero J, Wever-Pinzon O, Korniyenko A, Berrios RS,
Rep. 2020; 6(10): 1091-1094. doi: 10.1016/j.jdcr.2020.07.042. et al. Meta-analysis of randomized trials of angioedema as an adverse event
4. Adeliño R, Andrés-Cordón JF, Aracelis De La Cruz Martínez C. Acute of renin-angiotensin system inhibitors. Am J Cardiol. 2012; 110(3): 383-91.
urticaria with angioedema in the setting of coronavirus disease 2019. doi: 10.1016/j.amjcard.2012.03.034.

12 Rev Esp Casos Clin Med Intern (RECCMI). 2021 (Abril); 6(1): 10-12